JP2019508481A - ステープルまたはステッチペプチドに複合された生物活性化合物 - Google Patents

ステープルまたはステッチペプチドに複合された生物活性化合物 Download PDF

Info

Publication number
JP2019508481A
JP2019508481A JP2018550872A JP2018550872A JP2019508481A JP 2019508481 A JP2019508481 A JP 2019508481A JP 2018550872 A JP2018550872 A JP 2018550872A JP 2018550872 A JP2018550872 A JP 2018550872A JP 2019508481 A JP2019508481 A JP 2019508481A
Authority
JP
Japan
Prior art keywords
dccpm
pmo
peptide
bac
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018550872A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2017109494A5 (cg-RX-API-DMAC7.html
JP2019508481A5 (cg-RX-API-DMAC7.html
Inventor
フォスター，キース
エイラース，ウーター
ジェームズ レジナルド ガッド，アダム
ジェームズ レジナルド ガッド，アダム
Original Assignee
スツラ セラポーティクス エルティーディー
スツラ セラポーティクス エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スツラ セラポーティクス エルティーディー, スツラ セラポーティクス エルティーディー filed Critical スツラ セラポーティクス エルティーディー
Publication of JP2019508481A publication Critical patent/JP2019508481A/ja
Publication of JP2019508481A5 publication Critical patent/JP2019508481A5/ja
Publication of JPWO2017109494A5 publication Critical patent/JPWO2017109494A5/ja
Priority to JP2023014917A priority Critical patent/JP2023055874A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
JP2018550872A 2015-12-21 2016-12-21 ステープルまたはステッチペプチドに複合された生物活性化合物 Pending JP2019508481A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023014917A JP2023055874A (ja) 2015-12-21 2023-02-02 ステープルまたはステッチペプチドに複合された生物活性化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1522548.5A GB2545898B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
GB1522548.5 2015-12-21
PCT/GB2016/054028 WO2017109494A1 (en) 2015-12-21 2016-12-21 Biologically active compound conjugated to a stapled or stitched peptide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023014917A Division JP2023055874A (ja) 2015-12-21 2023-02-02 ステープルまたはステッチペプチドに複合された生物活性化合物

Publications (3)

Publication Number Publication Date
JP2019508481A true JP2019508481A (ja) 2019-03-28
JP2019508481A5 JP2019508481A5 (cg-RX-API-DMAC7.html) 2020-02-13
JPWO2017109494A5 JPWO2017109494A5 (cg-RX-API-DMAC7.html) 2022-06-16

Family

ID=55311362

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018550872A Pending JP2019508481A (ja) 2015-12-21 2016-12-21 ステープルまたはステッチペプチドに複合された生物活性化合物
JP2023014917A Pending JP2023055874A (ja) 2015-12-21 2023-02-02 ステープルまたはステッチペプチドに複合された生物活性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023014917A Pending JP2023055874A (ja) 2015-12-21 2023-02-02 ステープルまたはステッチペプチドに複合された生物活性化合物

Country Status (10)

Country Link
US (2) US11541124B2 (cg-RX-API-DMAC7.html)
EP (1) EP3393520A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019508481A (cg-RX-API-DMAC7.html)
KR (1) KR20180091920A (cg-RX-API-DMAC7.html)
CN (1) CN108472385A (cg-RX-API-DMAC7.html)
AU (1) AU2016375869B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018012641A2 (cg-RX-API-DMAC7.html)
CA (1) CA3007910A1 (cg-RX-API-DMAC7.html)
GB (1) GB2545898B (cg-RX-API-DMAC7.html)
WO (1) WO2017109494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
SG11201906200WA (en) 2017-01-06 2019-08-27 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
WO2019084528A1 (en) 2017-10-27 2019-05-02 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR INTRACELLULAR ADMINISTRATION OF STAPLED PEPTIDES
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
WO2020047399A1 (en) * 2018-08-31 2020-03-05 Massachusetts Institute Of Technology Ionizable lipidoids and their uses
WO2020215005A1 (en) * 2019-04-18 2020-10-22 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
KR102499670B1 (ko) * 2019-06-17 2023-02-20 고려대학교 산학협력단 라이신 치환을 포함하는 Romo1 유래 항균 펩타이드 및 그 변이체
KR102521182B1 (ko) * 2020-11-06 2023-04-12 서울대학교산학협력단 결핵균 독소-항독소 시스템을 표적으로 하는 항균 스테이플 펩타이드 및 이의 용도
WO2024069229A2 (en) 2022-08-03 2024-04-04 Sutura Therapeutics Ltd Biologically active compounds
WO2025027389A1 (en) 2023-08-03 2025-02-06 Sutura Therapeutics Limited Biologically active compounds comprising a stapled or stitched peptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
WO2016187425A1 (en) * 2015-05-19 2016-11-24 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972779A3 (en) * 1987-10-28 2004-10-20 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
ES2639852T3 (es) * 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
US20110250685A1 (en) * 2008-06-03 2011-10-13 Nash Huw M Compositions and methods for enhancing cellular transport of biomolecules
EP2762567B1 (en) 2008-10-24 2016-07-13 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
WO2010123369A1 (en) * 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
WO2011111874A1 (ja) 2010-03-11 2011-09-15 独立行政法人理化学研究所 細胞膜透過性ダンベル型rnaおよびその製造方法
KR20130103662A (ko) * 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
CN103619356B (zh) 2011-05-05 2017-09-12 萨勒普塔医疗公司 肽寡核苷酸缀合物
EP2751128B1 (en) * 2011-08-30 2021-03-03 United Kingdom Research and Innovation Cell-penetrating peptides having a central hydrophobic domain
CN103121959B (zh) * 2011-11-21 2016-09-21 昆山市工业技术研究院小核酸生物技术研究所有限责任公司 化合物和核酸复合分子与核酸复合物及其制备方法和应用
WO2014053879A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
JP2016503394A (ja) * 2012-10-26 2016-02-04 エヌライフ、セラピューティックス、ソシエダッド、リミターダＮｌｉｆｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｓ．Ｌ． 細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法
CN103626850B (zh) 2013-04-03 2015-08-26 安徽省新星药物开发有限责任公司 具有细胞穿透功能的多肽及其在药物递送中的用途
BR112018000691A2 (pt) 2015-07-15 2018-09-18 Protagonist Therapeutics Inc inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
GB2563875B (en) 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
WO2016187425A1 (en) * 2015-05-19 2016-11-24 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEM., vol. 17, JPN6021047579, 2006, pages 750 - 758, ISSN: 0004891091 *
CHEM. REV., vol. 106, JPN6021047576, 2006, pages 3712 - 3761, ISSN: 0004891090 *
CHU, QIAN: "I. Targeted β-catenin Ubiquitination and Degradation Using Bifunctional Stapled Peptides II. Studie", DOCTORAL DISSERTATION, HARVARD UNIVERSITY, JPN6020050533, November 2013 (2013-11-01), pages 1 - 153, ISSN: 0004891092 *
CURR. GENE THER., vol. 12, JPN6021047585, 2012, pages 161 - 178, ISSN: 0004891088 *
CURR. PHARM. DES., vol. 19, JPN6021047588, 2013, pages 2948 - 2962, ISSN: 0004891087 *
J. AM. CHEM. SOC., vol. 136, JPN6020050531, 2014, pages 12314 - 12322, ISSN: 0004891093 *
MED. CHEM. COMMUN., vol. 6, JPN6021047581, June 2015 (2015-06-01), pages 111 - 119, ISSN: 0004891089 *

Also Published As

Publication number Publication date
WO2017109494A1 (en) 2017-06-29
AU2016375869B2 (en) 2023-07-13
BR112018012641A2 (pt) 2018-12-04
US20230158166A1 (en) 2023-05-25
US20200353092A1 (en) 2020-11-12
JP2023055874A (ja) 2023-04-18
CA3007910A1 (en) 2017-06-29
GB2545898B (en) 2019-10-09
GB2545898A (en) 2017-07-05
EP3393520A1 (en) 2018-10-31
GB201522548D0 (en) 2016-02-03
US11944688B2 (en) 2024-04-02
KR20180091920A (ko) 2018-08-16
US11541124B2 (en) 2023-01-03
CN108472385A (zh) 2018-08-31
AU2016375869A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
US11944688B2 (en) Biologically active compounds
JP6715325B2 (ja) ｓｉＲＮＡ、ｓｉＲＮＡを含む医薬組成物及び結合体、並びにそれらの応用
CA2846218C (en) Cell-penetrating peptides having a central hydrophobic domain
US8575305B2 (en) Cell penetrating peptides
JP2023126866A (ja) 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物
JPWO2017109494A5 (cg-RX-API-DMAC7.html)
JPWO2019002875A5 (cg-RX-API-DMAC7.html)
WO2024069229A2 (en) Biologically active compounds
GB2574525A (en) Improvements in drug delivery
GB2580569A (en) Improvements in drug delivery
WO2025076243A1 (en) Cell-targeting complexes and uses thereof
HK1194389B (en) Cell-penetrating peptides having a central hydrophobic domain
HK1194389A (en) Cell-penetrating peptides having a central hydrophobic domain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191220

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220302

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221006